AZD9150 plus Durvalumab alone or in Combination with Chemotherapy in Patients with Advanced, Solid Tumours and in Patients with Non-Small-Cell Lung Cancer

Trial Identifier: D5660C00016
Sponsor: AstraZeneca
NCTID:: NCT03421353
Start Date: February 2018
Primary Completion Date: January 2020
Study Completion Date: March 2024
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
US, IN Lafayette, IN, US, 47905
US, OK Oklahoma City, OK, US, 73104
US, TN Nashville, TN, US, 37203
US, TX Dallas, TX, US, 75230
US, TX Houston, TX, US, 77030
US, VA Fairfax, VA, US, 22031